The LXM.5 pilot study reveals an 80% bioavailability increase compared to competing products combining levodopa and carbidopa. The study additionally shows sustained and smooth levodopa levels in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback